This rich one-day PRISMAP public event included news about PRISMAP, reports by PRISMAP users about their projects and scientific sessions about radiochemistry and nuclear medicine made in Nantes.
For the first part, we had the pleasure to welcome five of our users to listen at their innovative and original results obtained thanks to the support and supply of radionuclides from PRISMAP’s partner institutes. Dr Margarita Kirienko (Fondazione IRCCS Instituto Nazionale dei Tumori, Milano, Italy) presented the results she obtained with the use of Tb-161 in view of treatment of prostate cancer. Dr Mylene Richard and Dr Bertrand Kuhnast (CEA, Service Hospitalier Frédéric Joliot, Orsay, France) presented new results related to their ScandAl project on Sc-43 antibody -fragment labelling. Dr Eleni Gourni (Universitätklinik für Nuklearmedizin, Bern, Switzerland) presented ground-breaking development in theranostics using scandium radionuclides. Dr Filipe Elvas (University of Antwerp, Belgium) presented the results from its two projects involving At-221 and Cu-67 provided by PRISMAP both aiming in improving the theranostic approach. Dr Clement Morgat (University of Bordeaux, France) showed new results obtained using Tb-161 and zebrafish embryos as a novel model to evaluate the efficacy of short-range emitters used for targeted radionuclide therapy.
For the second and third part of our public event, you can download the presentations directly from the agenda below.
The meeting can be attended in-person or remotely.